AGWCA
INKT icon

Annis Gardner Whiting Capital Advisors’s MiNK Therapeutics INKT Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$2.11K – 785
2026
Q1 		$2.11K Buy
+200
New +$2.23K ﹤0.01% 1050

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's INKT Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of MiNK Therapeutics (INKT) in Q2 2026, closing a stake of 200 shares — an estimated $2.11K sold.

Annis Gardner Whiting Capital Advisors first reported a position in INKT in Q1 2026 and held it in 1 quarter. The position peaked at $2.11K in Q1 2026. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining MiNK Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 200 MiNK Therapeutics shares in Q2 2026, an estimated $2.11K.
  • Annis Gardner Whiting Capital Advisors first reported a position in MiNK Therapeutics in Q1 2026 and held it in 1 quarter.
  • Annis Gardner Whiting Capital Advisors's MiNK Therapeutics position peaked at $2.11K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.